» Articles » PMID: 27856683

The Challenging Experience Questionnaire: Characterization of Challenging Experiences with Psilocybin Mushrooms

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2016 Nov 19
PMID 27856683
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.

Citing Articles

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.

Strickland J, Garcia-Romeu A, Johnson M Psychedelic Med (New Rochelle). 2025; 2(1):33-43.

PMID: 40051759 PMC: 11658653. DOI: 10.1089/psymed.2023.0046.


The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.

Ramarushton B, Blumenthal H, Ryals A, Boals A, Thompson L Psychedelic Med (New Rochelle). 2025; 2(3):146-152.

PMID: 40051683 PMC: 11658672. DOI: 10.1089/psymed.2024.0009.


Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.

Piercey C, Gray B, Sung A, Henry D, Karoly H Psychedelic Med (New Rochelle). 2025; 2(4):234-242.

PMID: 40051484 PMC: 11658379. DOI: 10.1089/psymed.2023.0052.


Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).

Holas P, Kaminska J, Zajenkowski M Dialogues Clin Neurosci. 2025; 27(1):11-21.

PMID: 40051051 PMC: 11892042. DOI: 10.1080/19585969.2025.2470426.


Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.

Weintraub M, Jeffrey J, Grob C, Ichinose M, Bergman R, Cooper Z Psychedelic Med (New Rochelle). 2025; 1(4):230-240.

PMID: 40046861 PMC: 11658652. DOI: 10.1089/psymed.2023.0018.


References
1.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B . Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016; 30(12):1165-1180. PMC: 5367551. DOI: 10.1177/0269881116675512. View

2.
Pahnke W, Kurland A, GOODMAN L, Richards W . LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther. 1969; 9:144-52. View

3.
Carbonaro T, Bradstreet M, Barrett F, MacLean K, Jesse R, Johnson M . Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12):1268-1278. PMC: 5551678. DOI: 10.1177/0269881116662634. View

4.
BELLEVILLE R . MMPI score changes induced by lysergic acid diethylamide (LSD-25). J Clin Psychol. 1956; 12(3):279-82. DOI: 10.1002/1097-4679(195607)12:3<279::aid-jclp2270120315>3.0.co;2-8. View

5.
Strassman R, Qualls C, Uhlenhuth E, Kellner R . Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994; 51(2):98-108. DOI: 10.1001/archpsyc.1994.03950020022002. View